Security key
171126204
Pelthos Therapeutics Inc. - Common Stock, par value $0.0001 per share (PTHS)
CUSIP: 171126204
Q2 2026 13F Holders as of 30 Jun 2026
- Security type / class
- Equity / Common Stock, par value $0.0001 per share
- Total 13F shares
- 1,323,157
- Total 13F value
- $37,392,417
- Share change
- +410,846
- SEC-reported price per share
- $28.26
- Number of holders
- 23
- Value change
- +$11,624,481
- Number of buys
- 15
- Number of sells
- 6
- Shares outstanding
- 3,332,442
Holder snapshot
6 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q2 2026
Institutions
23
Top holders
10
PTHS full security history
Ownership snapshot
Full 13F holder table
Previous quarter: Q1 2026
Pelthos Therapeutics Inc. SEC filings
Pelthos Therapeutics Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 171126204
Recent filing periods:
Ownership snapshot
Top reported holders of PTHS - Pelthos Therapeutics Inc. - Common Stock, par value $0.0001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
LIGAND PHARMACEUTICALS INC
Disclosed value leader
LIGAND PHARMACEUTICALS INC
Comparable rows
15/15
Latest evidence
10 Apr 2026
13D/G
3/4/5
13F
Lead comparable stake: 50%
13D/G row: LIGAND PHARMACEUTICALS INC
Showing 1-6 of 15 holder rows.
Quick read
LIGAND PHARMACEUTICALS INC leads the comparable SEC ownership view at 50%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens LIGAND PHARMACEUTICALS INC's linked filing trail.
Comparable ownership
Top 5
LIGAND PHARMACEUTICALS INC
50%
3i, LP
9.9%
Alexandra Wood (Canada) Inc.
9.5%
Murchinson Ltd.
9.1%
Ezra M. Friedberg
8.3%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| LIGAND PHARMACEUTICALS INC |
13D/G
3/4/5
Ligand Pharmaceuticals Incorporated · Director, 10%+ Owner
|
50%
|
$145,296,959
5,189,177 shares
|
+$7,316,652 | 06 Nov 2025 |
| 3i, LP |
13D/G
|
9.9%
|
$7,751,598
337,026 shares
|
+$417,220 | 31 Mar 2026 |
| Alexandra Wood (Canada) Inc. |
13D/G
|
9.5%
|
$734,959
574,187 shares
|
$0 | 13 Dec 2024 |
| Murchinson Ltd. |
13D/G
13F
Company
|
9.1%
|
$7,840,000
280,000 shares
|
$0 | 30 Sep 2025 |
| Ezra M. Friedberg |
13D/G
Ezra Friedberg
|
8.3%
|
—
250,121 shares
|
$0 | 01 Jul 2025 |
| Ikarian Capital, LLC |
13D/G
13F
Company
|
7.7%
|
$5,901,754
256,598 shares
|
+$19,320 | 31 Mar 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q2 2026
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
23
Shares
1,323,157
Rows available
23
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q2 2026 vs Q1 2026 Across Filers
Q1 2026 holders
17
Q2 2026 holders
23
Holder diff
6
| Investor | Q1 2026 Shares | Q2 2026 Shares | Share Diff | Share Chg % | Q1 2026 value | Q2 2026 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend